Stay updated with breaking news from High Acuity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Equities researchers at StockNews.com started coverage on shares of Amedisys (NASDAQ:AMED – Free Report) in a research report issued to clients and investors on Monday. The brokerage set a “buy” rating on the health services provider’s stock. AMED has been the subject of a number of other reports. Benchmark downgraded shares of Amedisys from a […]
/PRNewswire/ -- The Dungarvin organization, a group of companies providing community-based services for people with disabilities in 15 states, has announced a...
Benchmark lowered shares of Amedisys (NASDAQ:AMED – Free Report) from a buy rating to a hold rating in a research note released on Tuesday, The Fly reports. A number of other research analysts have also recently commented on AMED. Truist Financial upped their target price on Amedisys from $97.00 to $101.00 in a research note […]
Amedisys (NASDAQ:AMED – Free Report) had its price target increased by Truist Financial from $97.00 to $101.00 in a report released on Tuesday morning, The Fly reports. A number of other equities analysts also recently weighed in on AMED. Stephens reaffirmed an equal weight rating and issued a $103.00 price target on shares of Amedisys […]
Amedisys (NASDAQ:AMED – Free Report) had its price target boosted by Barclays from $88.00 to $101.00 in a research report released on Tuesday, The Fly reports. Other research analysts have also recently issued reports about the stock. Cantor Fitzgerald increased their price target on shares of Amedisys from $91.00 to $100.00 in a report on […]